Every Form 4 that OS Therapies Incorporated (OSTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OSTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSTX filings page.
McKean-Dieser Avril Suzette reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Search Theodore F. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Ciccio John reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Acevedo Christopher P. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
PETIT ROBERT reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 100,000 shares. Following the reported transactions, holdings were 100,000 shares.
Romness Paul A. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 1,000,000 shares. Following the reported transactions, holdings were 1,000,000 shares.
Jarry Olivier Roger reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
Galzahr Karim reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
OS Therapies President and CEO Paul A. Romness reported an amended insider transaction reflecting a grant of 1,000,000 stock options on October 21, 2025. The options have an exercise price of $1.8 per share, are fully vested on the one-year anniversary of the grant date, and expire on October 21, 2035, assuming continued employment on the vesting date. Following this award, Romness beneficially owned 2,473,000 shares of common stock directly. The amendment corrects an earlier filing that had misreported the number of shares underlying this stock option grant.
OS Therapies Inc. director reports new stock option grant and holdings. Theodore F. Search, a director of OS Therapies Inc., reported receiving stock options on 10/21/2025 to buy 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as he is still serving as a director on that date, and expire on 10/21/2035.
After this grant, he beneficially owns 140,000 stock options directly. He also reports beneficial ownership of 20,000 common shares directly and 435,835 common shares indirectly through Mill River Partners LLC, where he serves on the board of managers and shares voting and investment power.
OS Therapies Inc. filed a report showing that senior officer Robert Petit, the company’s Chief Medical Officer and Chief Scientific Officer, received a new equity award. On October 21, 2025, he was granted stock options to purchase 500,000 shares of OS Therapies common stock at an exercise price of $1.80 per share.
The options are scheduled to vest in full on the one-year anniversary of the grant date, as long as he is still employed by OS Therapies at that time. After this transaction, Petit also holds 200,000 shares of OS Therapies common stock directly, in addition to the newly granted options.
OS Therapies Inc. reported an insider equity award for its President and CEO, who is also a director. On October 21, 2025, the executive received stock options to purchase 1,950,000 shares of OS Therapies common stock at an exercise price of $1.8 per share. These options expire on October 21, 2035 and vest in full on the one-year anniversary of the grant date, as long as the executive remains employed by the company on that date.
Following this grant, the reporting person holds 2,473,000 shares of common stock directly, in addition to the newly granted 1,950,000 stock options, reflecting a significant personal equity stake in OS Therapies.
OS Therapies Inc director reports stock option grant. A director of OS Therapies Inc (OSTX) reported receiving stock options to purchase 140,000 shares of the company’s common stock on October 21, 2025, at an exercise price of $1.80 per share. The options vest in full on the one-year anniversary of the grant date, as long as the director is still serving on the board at that time, and are scheduled to expire on October 21, 2035.
OS Therapies Inc. director receives new stock option grant. A reporting person serving as a director of OS Therapies Inc. (ticker OSTX) was granted stock options on October 21, 2025 to purchase 140,000 shares of the company’s common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as the individual continues to serve as a director on that date, and are scheduled to expire on October 21, 2035. Following this grant, the director beneficially owns 140,000 stock options directly.
OS Therapies Inc director reports new stock option grant and holdings. On October 21, 2025, director John Ciccio was granted stock options to buy 140,000 shares of OS Therapies Inc common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, if he is still serving as a director on that date, and expire on October 21, 2035.
After the reported transactions, he beneficially owns 435,835 shares of common stock indirectly through Mill River Partners LLC and 20,000 shares directly, in addition to the 140,000 stock options held directly.
OS Therapies Inc. reported that its Chief Financial Officer received a new stock option grant. On October 21, 2025, the reporting person was granted options to purchase 200,000 shares of OS Therapies common stock at an exercise price of $1.8 per share, under a stock option award agreement.
The options vest in full on the one-year anniversary of the grant date, as long as the individual is still serving as an employee on that date. Following this grant, the reporting person holds 109,375 shares of common stock directly and 200,000 stock options directly.
OS Therapies Inc director Avril McKean-Dieser reported new equity awards and current holdings. As of the reported transactions, the director beneficially owns 5,000 shares of OS Therapies common stock in direct ownership. On October 21, 2025, the director was granted stock options to purchase 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, provided the director is still serving on the board at that time, and expire on October 21, 2035. The grant reflects part of the director’s equity-based compensation.